Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
The non-model organism “renaissance” has arrived
Meet 10 neuroscientists bringing model diversity back with the funky animals they study.
The non-model organism “renaissance” has arrived
Meet 10 neuroscientists bringing model diversity back with the funky animals they study.
Assembloids illuminate circuit-level changes linked to autism, neurodevelopment
These complex combinations of organoids afford a closer look at how gene alterations affect certain brain networks.
Assembloids illuminate circuit-level changes linked to autism, neurodevelopment
These complex combinations of organoids afford a closer look at how gene alterations affect certain brain networks.
Rajesh Rao reflects on predictive brains, neural interfaces and the future of human intelligence
Twenty-five years ago, Rajesh Rao proposed a seminal theory of how brains could implement predictive coding for perception. His modern version zeroes in on actions.
Rajesh Rao reflects on predictive brains, neural interfaces and the future of human intelligence
Twenty-five years ago, Rajesh Rao proposed a seminal theory of how brains could implement predictive coding for perception. His modern version zeroes in on actions.